Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis

Table 2 HbA1c levels of patients with T2DM at 3, 6, and 12 months after MSCs therapy

Follow-up (months)	Test for heterogeneity		Analysis model	Test for overall effect		WMD or SMD	95% CI
Follow-up (months)	I² (%)	P	Analysis model	Z	P	WMD or SMD	95% CI
3	87	0.006	Random	0.89	0.37	−0.60	(−1.92, 0.72)
6	85	<0.0001	Random	2.60	0.009	−1.30	(2.27, −0.32)
12	66	0.09	Random	1.72	0.09	−0.75	(−1.60, 0.11)

Abbreviations: HbA1c glycated hemoglobin, T2DM type 2 diabetes, MSCs mesenchymal stem cells, WMD weighted mean difference, SMD standard mean difference

ISSN: 1757-6512